Phase 4
Completed N=62
Effect of Nafamostat on Postreperfusion Syndrome (PRS)
Liver Transplantation · Postreperfusion Syndrome
Source: ClinicalTrials.gov NCT01001403 ↗
Enrolled (actual)
62
Serious AEs
0.0%
Results posted
May 2010
Primary outcomePrimary: Number of Participants With Moderate and Severe Postreperfusion Syndrome (PRS) — 15; 25 participants
Summary
This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Moderate and Severe Postreperfusion Syndrome (PRS) |
15; 25 | — |
Eligibility Criteria
Inclusion Criteria
- >= 18 year old scheduled to undergo liver transplantation
Exclusion Criteria
- Previous history of pulmonary, cardiovascular, or renal disease
- Previous history of allergic reactions to nafamostat
Data sourced from ClinicalTrials.gov (NCT01001403). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.